WO2016003181A1 - 활성성분-함유 필름 코팅층을 포함하는 복합제제 - Google Patents

활성성분-함유 필름 코팅층을 포함하는 복합제제 Download PDF

Info

Publication number
WO2016003181A1
WO2016003181A1 PCT/KR2015/006743 KR2015006743W WO2016003181A1 WO 2016003181 A1 WO2016003181 A1 WO 2016003181A1 KR 2015006743 W KR2015006743 W KR 2015006743W WO 2016003181 A1 WO2016003181 A1 WO 2016003181A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
polyvinyl alcohol
formulation
polyethylene glycol
coating layer
Prior art date
Application number
PCT/KR2015/006743
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
김형서
조정현
최영근
김경수
김진철
김용일
박재현
우종수
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to ES15816054T priority Critical patent/ES2772137T3/es
Priority to CN201580033728.7A priority patent/CN106659690B/zh
Priority to BR112016030731A priority patent/BR112016030731A2/pt
Priority to PL15816054T priority patent/PL3162363T3/pl
Priority to RU2016148824A priority patent/RU2696563C9/ru
Priority to EP15816054.9A priority patent/EP3162363B1/en
Priority claimed from KR1020150093778A external-priority patent/KR101780739B1/ko
Publication of WO2016003181A1 publication Critical patent/WO2016003181A1/ko
Priority to PH12016502537A priority patent/PH12016502537A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Definitions

  • the present invention relates to a composite formulation comprising an active ingredient-containing film coating layer and a method for producing the same, and more particularly, to an active ingredient-containing composition having a stable dissolution of the coating layer against external impacts and having an excellent dissolution rate of the active ingredient. It relates to a composite formulation comprising a film coating layer and a method of manufacturing the same.
  • Men's prostate is about the size of a walnut egg in young and grows larger with age.
  • 'Prostatic hyperplasia' is a disease in which the prostate enlarges with increasing age and the urethra passes inside the prostate, causing various symptoms. Means.
  • the cause of enlarged prostate is not yet clear, and as with other chronic diseases, several complex factors are known to work.
  • the cause of the pathology that has been recognized to date is due to the aging of normal functioning testicles. Since the prostate is a testosterone-dependent organ, it needs a constant male hormone to maintain its growth and function, and if male hormone is not produced by castration, the prostate contracts.
  • Symptoms of enlarged prostate include urinating urine at least 8 times a day, night urination, strong and sudden urine (feeling urinary) and urinary urges, urinary urge, urge incontinence, night urination, urination pain, etc.
  • Bladder storage disorders and delayed urination when urine occurs when urine is seen), sedation (breaking up of urine), abdominal urination (when urinating), urinary weakness, feeling of urination, Lower Urinary Tract Symptoms (LUTS) commonly referred to as bladder discharge disorders.
  • 5- ⁇ -reductase inhibitors are representative drugs used to treat prostatic hyperplasia and may be used alone, but may be tamsulosin or phosphodiesterase 5 inhibitors (e.g., Tadalafil, Vardenafil, Eudenafil, etc.) is known to be used in the treatment of effective prostatic hyperplasia.
  • tamsulosin or phosphodiesterase 5 inhibitors e.g., Tadalafil, Vardenafil, Eudenafil, etc.
  • 5- ⁇ -reductase inhibitors inhibit the conversion of testosterone to dihydrotestosterone, which further enhances prostate size-increasing activity, consequently inhibiting and thus increasing prostate size Relieves physical pressure on the urinary tract.
  • Tamsulosin is a drug that selectively inhibits ⁇ -adrenoceptor and acts selectively on the genitourinary system.It relaxes the smooth muscles and prostate gland surrounding the bladder, improving urinary excretion rate and improving the symptoms of benign prostatic hypertrophy. It is known to improve.
  • Tadalafil Calis, Lilly ICOS
  • Vardenafil Levitra, GSK
  • the film coating layer may be peeled or broken by a normal impact during the storage period of the product, thereby ensuring sufficient efficacy of the composite formulation. It may not be possible, and the product may be impossible to commercialize due to the deterioration of external properties. In addition, in order to ensure sufficient bioavailability and rapid effect during oral administration, very high dissolution rate of the active ingredient contained in the film coating layer in the combination may be required.
  • the present invention provides a composite formulation comprising an active ingredient-containing film coating layer having a high dissolution rate of the active ingredient while the properties of the coating layer are stable against external normal impacts.
  • the present invention provides a method for producing a composite formulation comprising the active ingredient-containing film coating layer.
  • a composite formulation comprising a film coating layer containing a second active ingredient
  • the film coating layer provides a composite formulation comprising a polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol.
  • It provides a method for producing a composite preparation according to the present invention comprising the step of coating the coating solution on the core.
  • the composite formulation according to one aspect of the present invention may not only have a tensile strength capable of withstanding the external impact of the active ingredient-containing film coating layer, but also ensure a high dissolution rate of the active ingredient contained in the film coating layer. Therefore, the combination preparation does not have a change in external properties even when the external impact is not only high marketability, there is no loss of drug efficacy, it is possible to secure sufficient bioavailability and rapid efficacy. As a result, the co-formulation may enable a good and effective co-formulation containing two or more active ingredients, thereby improving patient compliance with the co-administration of the drug.
  • FIG. 1 shows a second active agent on the surface of a composite formulation (a) coated with a film coating layer containing a second active ingredient on the surface of a tablet core containing the first active ingredient and a hard capsule core containing the first active ingredient. It is a schematic diagram which shows the composite agent (b) coated with the film coating layer containing a component.
  • Figure 2 is a photograph of an example of a composite agent determined as a good product (a) and a bad product (b) in the defect test of the present specification.
  • Figure 3 shows the defective rate when removing the package after PTP packaging the composite formulation of Comparative Examples 1 to 8.
  • Figure 4 shows the defective rate when removing the package after PTP packaging the composite formulation of Examples 1 to 10.
  • FIG. 5 shows the defective rate of each coating base material when PTP packaging the composite formulations of Comparative Examples 1 to 4 was stored for 1 week at 60 ° C. and 0% RH, and then the packaging was removed.
  • Figure 6 shows the dissolution rate of finasteride from the complex formulation of Comparative Examples 1 to 4.
  • Figure 7 shows the dissolution rate of finasteride from the combination formulation of Examples 2-5.
  • FIG. 8 shows the defective rate when removing the package after PTP packaging in order to observe the difference in the defective rate between the formulations of the core of the composite formulations of Examples 3, 11 and 12.
  • the present inventors have intensively studied coating bases that enable the active ingredient-containing film coating layer of a composite formulation comprising the active ingredient-containing film coating layer to ensure a high dissolution rate of the drug contained in the film coating layer while having sufficient tensile strength. It was. As a result, when a polyvinyl alcohol-polyethylene glycol graft copolymer and a polyvinyl alcohol are combined among many film coating bases, the tensile strength of the film coating layer is sufficiently strong, so that the film coating layer is peeled off or broken by a normal impact during the product storage period. Not only that, it was found that it is possible to ensure a high dissolution rate of the drug contained in the film coating layer.
  • a composite formulation comprising a film coating layer containing a second active ingredient
  • the film coating layer provides a composite formulation comprising a polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol.
  • the core containing the first active ingredient may be any pharmaceutical formulation commonly used in the pharmaceutical arts.
  • the core may be in the form of tablets, hard capsules or soft capsules, but is not limited thereto.
  • Filling portion filled in the hard capsule or soft capsule is typically any pharmaceutical formulation used in the pharmaceutical field may be granules, pellets, powders, tablets, solutions, or combinations thereof.
  • the core may be present at a rate of about 20 to 99.5 weight percent of the total coformulation.
  • the film coating layer containing the second active ingredient may be formed on the surface of the core.
  • the film coating layer contains a combination of polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol as a coating base.
  • the inventors have prepared a composite formulation in which a film coating layer comprising the second active ingredient and various coating bases is formed on a tablet or capsule core containing the first active ingredient, and then the poor test for each coating base and the preparation over time. 2 drug dissolution test was performed.
  • the coating base when the polyvinyl alcohol-polyethylene glycol graft copolymer, polyvinyl alcohol, povidone, and hypromellose alone are used as the coating base, the defective rate at which the film coating layer of the composite agent is peeled or broken from the core is 20 to 20. It was very high at 40% and only polyvinyl alcohol was very low at less than 2% (see Test Examples 1 and 3).
  • the polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol may be used in a weight ratio of about 8: 2 to 4: 6, specifically about 7: 3 to 4: 6 It may be used in a weight ratio of, and more specifically, may be used in a weight ratio of about 6: 4.
  • the polyvinyl alcohol-polyethylene glycol graft copolymer may be composed of about 65 to 85% polyvinyl alcohol units and about 15 to 35% polyethylene glycol units, and may include about 0.01 to 0.5% colloidal silica.
  • the weight average molecular weight may be about 35,000 to 55,000 daltons.
  • Polyvinyl alcohol-polyethylene glycol graft copolymer for example, as Kollicoat ® ahyial (Kollicoat IR; BASF) is commercially available, and the Collicoat ® IAL consists of about 75% polyvinyl alcohol units and about 25% polyethylene glycol units, contains about 0.3% colloidal silica, and has a weight average molecular weight of about 45,000 Daltons .
  • the polyvinyl alcohol may have a molecular weight of about 20,000 to 200,000 Daltons as a water-soluble polymer, the higher the molecular weight, the higher the viscosity.
  • the film coating layer may be present in a ratio of about 0.5 to 80 parts by weight based on 100 parts by weight of the core.
  • the co-formulation of the polyvinyl alcohol-polyethylene glycol graft copolymer is composed of about 65-85% polyvinyl alcohol units and 15-35% polyethylene glycol units, colloidal silica about 0.01- 0.5 wt%, the weight average molecular weight is about 35,000-55,000 Daltons, the polyvinyl alcohol has a molecular weight of about 20,000-200,000 Daltons, the weight ratio of polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol is about 7: 3-4: 6.
  • FIG. 1 A schematic diagram of a combination preparation according to one embodiment of the present invention is shown in FIG. 1.
  • Figure 1 (a) is a schematic diagram showing a composite formulation coated with a film coating layer containing a second active ingredient on the surface of the tablet core containing the first active ingredient.
  • Figure 1 (b) is a schematic diagram showing a composite formulation coated with a film coating layer containing a second active ingredient on the surface of the hard capsule core containing the first active ingredient.
  • the composite preparation according to the present invention may further include an inner skin that selectively separates the core and the film coating layer in order to more effectively prevent the interaction of the active ingredient.
  • the inner skin may be present in a ratio of about 0.01 to 60 parts by weight relative to 100 parts by weight of the core.
  • Film forming materials (film formers and / or coating agents) that can be used on the inner skin include hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, cellulose acetate phthalate, ethylcellulose, methylcellulose, polymethacrylate, Polyethyleneglycol, talc, titanium dioxide or mixtures thereof may be exemplified.
  • any of those generally used in the pharmaceutical field may be used in formulating oral or parenteral solid preparations.
  • the combination according to the present invention may optionally further include an outer skin on the outer side of the active ingredient-containing film coating layer to further protect the combination from the outside.
  • the outer skin portion may be any coating layer that does not significantly affect the high tensile strength of the active ingredient-containing film coating layer and the high dissolution rate of the active ingredient. Examples of such a coating may be a moisture proof coating, a light coating, or the like, and a person skilled in the art may select a coating base appropriately based on a known technique according to the type of coating.
  • the skin portion may be present in a ratio of about 0.01 to 60 parts by weight relative to 100 parts by weight of the core.
  • the complex formulation of the present invention may further comprise a pharmaceutically acceptable additive to the core and the active ingredient-containing film coating layer, in addition to the components.
  • the additive may be selected from the group consisting of diluents, disintegrants, binders, stabilizers, lubricants, and any combination thereof.
  • the diluent may be selected from the group consisting of microcrystalline cellulose, lactose, rudipress, mannitol, calcium dihydrogen phosphate, starch, low-substituted hydroxypropyl cellulose, and any combination thereof, but is not limited thereto.
  • the disintegrant may be selected from the group consisting of crospovidone, sodium starch glyconate, croscarmellose sodium, low-substituted hydroxypropyl cellulose, starch, alginic acid, sodium alginate, and any combination thereof, but is not limited thereto. It doesn't happen.
  • the binder is a silicate such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, copovidone, macrogol, hard anhydrous silicic acid, synthetic aluminum silicate, calcium silicate metasilicate aluminate, magnesium metasilicate aluminate It may be selected from the group consisting of derivatives, phosphates such as calcium hydrogen phosphate, carbonates such as calcium carbonate, and any combination thereof, but is not limited thereto.
  • the stabilizer may be selected from the group consisting of magnesium carbonate, sodium bicarbonate, sodium carbonate, calcium carbonate and any combination thereof, which is a basic stabilizer, but is not limited thereto.
  • the glidants include stearic acid metal salts such as stearic acid, calcium stearate or magnesium stearate, talc, colloidal silica, sucrose fatty acid esters, hydrogenated vegetable oils, high melting point waxes, glyceryl fatty acid esters, glycerol dibehe Nate and any combination thereof, but is not limited thereto.
  • stearic acid metal salts such as stearic acid, calcium stearate or magnesium stearate, talc, colloidal silica, sucrose fatty acid esters, hydrogenated vegetable oils, high melting point waxes, glyceryl fatty acid esters, glycerol dibehe Nate and any combination thereof, but is not limited thereto.
  • active ingredient may include not only pharmacologically active agents for therapeutic purposes, but also all reagents and other medical preparations that can be administered to the human body for the purpose of diagnosis, prevention, and the like.
  • the term also broadly refers to health functional food preparations as raw materials, ingredients or processed formulations thereof which are ingested for the purpose of obtaining useful effects for health purposes such as regulating nutrients or performing physiological actions on the structure and function of the human body. It may include.
  • first active ingredient and second active ingredient are intended to distinguish two or more active ingredients included in a combination preparation, and indicate the active ingredient contained in the core of the composite preparation in the first active ingredient and the film coating layer.
  • the active ingredient contained in is referred to as a second active ingredient for convenience.
  • the first active ingredient and the second active ingredient may be applied to any drug requiring combination administration, for example metformin and rosuvastatin, fenofibric acid and rosuvastatin, omega-3 and rosuvastatin, amlodipine and Lozatan, clopidogrel and aspirin, metformin and glyphlenamide, naloxone and oxycodone, fexofenadine and montelukast, brinzolamide and timolol, lercanidipine and enalapril, tamsulosin and 5-alpha-reductase inhibitors, phospho Diesterase 5 inhibitors and 5-alpha-reductase inhibitors, naproxen and esomeprazole, metformin and glypenclamide, and the like can be used.
  • Each of the first active ingredient and the second active ingredient may include a single ingredient, or may include a plurality of ingredients, if necessary.
  • the combination formulation is for oral administration.
  • the second active ingredient is a 5- ⁇ -reductase inhibitor
  • the first active ingredient may be any drug that requires coadministration with the 5- ⁇ -reductase inhibitor, for example tamsulosin (Tamsulosin) or phosphodiesterase 5 inhibitors (eg tadalafil, vardenafil, eudenafil, sildenafil, etc.).
  • tamsulosin tamsulosin
  • phosphodiesterase 5 inhibitors eg tadalafil, vardenafil, eudenafil, sildenafil, etc.
  • the first active ingredient is tamsulosin or a pharmaceutically acceptable salt thereof, and the second active ingredient is a 5- ⁇ -reductase inhibitor.
  • the 5- ⁇ -reductase inhibitor may be selected from the group consisting of finasteride, dutasteride, alphatradiol, and combinations thereof.
  • the dissolution rate of the 5- ⁇ -reductase inhibitor may be about 75% or more in 15 minutes.
  • the co-formulations are about 0.1 to 0.8 mg of tamsulosin or a pharmaceutically acceptable salt thereof as tamsulosin free base, considering the known daily dosage. More specifically, 0.2 mg to 0.6 mg, and may contain about 1 to 10 mg of finasteride as the second active ingredient.
  • the co-formulation of the present invention considering the known daily dosage, 0.1 to Tamsulosin or a pharmaceutically acceptable salt thereof as the first active ingredient as a tamsulosin free base 0.8 mg, more specifically about 0.2 mg to 0.6 mg, and may include about 0.2 to 0.6 mg of dutasteride as the second active ingredient.
  • the first active ingredient is a phosphodiesterase 5 inhibitor
  • the second active ingredient is a 5- ⁇ -reductase inhibitor.
  • the phosphodiesterase 5 inhibitor may be tadalafil, vardenafil, udenafil, sildenafil or any combination thereof, in one embodiment tadalafil.
  • the tadalafil may be used in the form of the free base of the tadalafil, but may also be used as a pharmaceutically acceptable salt, for example, hydrobromide, phosphate, sulfate, hydrochloride, malate, fumarate, lactate, tartrate , Citrate, besylate, camsylate, gluconate, and the like, and preferably, tadalafil glass, but is not limited thereto.
  • a pharmaceutically acceptable salt for example, hydrobromide, phosphate, sulfate, hydrochloride, malate, fumarate, lactate, tartrate , Citrate, besylate, camsylate, gluconate, and the like, and preferably, tadalafil glass, but is not limited thereto.
  • the 5- ⁇ -reductase inhibitor may be selected from the group consisting of finasteride, dutasteride, alphatradiol, and combinations thereof.
  • the dissolution rate of the 5- ⁇ -reductase inhibitor may be about 75% or more in 15 minutes.
  • the co-formulations are about 5 to 20 mg of tadalafil or a pharmaceutically acceptable salt thereof as tadalafil free base, more specifically, given a known daily dosage, more specifically May comprise 5 mg to 10 mg, and may comprise about 1 to 10 mg of finasteride as the second active ingredient.
  • the co-formulation of the present invention considering the known daily dosage, about 5 to 20 mg of tadalafil or a pharmaceutically acceptable salt thereof as tadalafil free base, as a first active ingredient, More specifically, it may include 5 mg to 10 mg, and may include about 0.2 to 0.6 mg of dutasteride as the second active ingredient.
  • the co-formulation comprises tamsulosin or a pharmaceutically acceptable salt thereof as a first active ingredient, a 5- ⁇ -reductase inhibitor as a second active ingredient, a film coating layer
  • the polyvinyl alcohol-polyethylene glycol graft copolymer of about 65-85% of polyvinyl alcohol units and about 15-35% of polyethylene glycol units comprises about 0.01-0.5% by weight of colloidal silica, and the weight average molecular weight is It is about 35,000-55,000 Daltons, the polyvinyl alcohol of the film coating layer has a molecular weight of about 20,000-200,000 Daltons, and the weight ratio of polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol is about 7: 3-4: 6.
  • One embodiment of the present invention comprising tamsulosin or a pharmaceutically acceptable salt thereof, or a phosphodiesterase 5 inhibitor as a first active ingredient, and a 5- ⁇ -reductase inhibitor as a second active ingredient
  • the combination preparation according to the present invention is excellent in tensile strength of the coating layer, and has excellent properties and stability, and obtains immediate release of the 5- ⁇ -reductase inhibitor, as well as two different prostatic hypertrophy drugs. All of the formulations can provide a synergistic effect in the treatment and alleviation of prostatic hyperplasia, thereby increasing patient compliance.
  • It provides a method for producing a composite preparation according to the present invention comprising the step of coating the coating solution on the core.
  • the core may use any core that may be used as a core in the pharmaceutical field, and may be, for example, in the form of a tablet, a hard capsule, or a soft capsule, but is not limited thereto. Preparation of such a core may use any preparation available as a commercially available core, and may manufacture it directly.
  • the core may be manufactured by a person skilled in the art according to the type of core using a technique known in the pharmaceutical field.
  • the solvent may be any solvent that is pharmaceutically acceptable while dissolving the second active ingredient, polyvinyl alcohol-polyethylene glycol graft copolymer, and polyvinyl alcohol.
  • the solvent water, ethanol, methanol, chloroform, dimethyl sulfoxide (DMSO) or a mixture thereof may be used. In one embodiment, water, ethanol, or a mixture thereof may be used, but is not limited thereto.
  • the coating method in the coating step may be any film coating technique commonly used in the pharmaceutical field.
  • a pan-coating method, a fluidized-bed coating method, a press-coating method, and the like are not limited thereto.
  • finasteride typically has teratogenicity, and therefore, a manufacturer must have a separate and independent production line so as not to be incorporated into other medicines when manufacturing the finasteride-containing preparation.
  • a manufacturer when manufacturing as a solid preparation, all processes such as mixing, granulating, tableting and coating must be carried out in a separate workshop. Since the preparation method of the composite preparation according to the present invention is applied by coating the finasteride with the coating solution containing finasteride, it is possible to prepare the finasteride formulation relatively simply since it is necessary to secure a coating facility for coating the finasteride separately in the existing manufacturing facility. . Therefore, according to the method for preparing a co-formulation according to the present invention, there is an advantage that the 5- ⁇ -reductase inhibitor-containing co-agent can be produced more economically.
  • Example 1-10 Preparation of a Co-Formulation with a 5- ⁇ -Reductase Inhibitor-Containing Film Coating Layer Coated on Tamsulosin Hydrochloride Capsule Core (1)
  • the prepared capsules were dried at 35 ° C. for 30 minutes to prepare a composite formulation in which a film coating layer containing 5- ⁇ -reductase inhibitor was coated on the tamsulosin capsule core.
  • Comparative Example 1-8 Preparation of a Co-Formulation with a 5- ⁇ -Reductase Inhibitor-Containing Film Coating Layer Coated on Tamsulosin Hydrochloride Capsule Core (2)
  • each formulation was packaged with PTP by sealing with an aluminum film in an aluminum mold using a PTP packaging machine (Lab-Blister machine, OMAR FANTASY PLUS). Ten randomly selected public testers using the packaged formulations were tested to destroy 100 PTP packages for each formulation to release the packaged drug. In the test, as shown in Fig. 2, the film coating layer was peeled off from the core or damaged by itself.
  • FIG. 2 shows a photograph of an example of a composite agent determined as a good product (a) and a defective product (b).
  • Comparative Examples 1, 3, 4, 5, 7, and 8 using Colicoat ® IAL, povidone and hypromellose as the sole coating base materials from the results of Table 3 and FIG. 3 are all about 20 to 20, respectively. It was found that the film coating layer was damaged at a high defective rate of 40%. On the other hand, Comparative Examples 2 and 6 using polyvinyl alcohol as the sole coating base material showed a low defective rate of about 2% or less.
  • Test Example 2 Poor Test of a Composite Preparation Comprising a Combination of Polyvinyl Alcohol-Polyethylene Glycol Graft Copolymer and Polyvinyl Alcohol as a Coating Base
  • Test Example 3 Defective Testing by Coating Base Under Harsh Conditions
  • Comparative Example 2 using the polyvinyl alcohol as a coating base exhibited a defective rate of 17.4%, showing excellent properties and stability compared to Comparative Example 1, Comparative Example 3 and Comparative Example 4.
  • the test solution was prepared by using 900 mL of distilled water according to the 10th amendment of Korea Pharmacopoeia and proceeded at a speed of 50 rpm in accordance with the general release formulation.
  • the test solution is collected at 0, 5, 10, 15, 30, 45 and 60 minutes after the start of the test and analyzed according to the 'liquid chromatograph method' in the 10 amendments of the Korean Pharmacopoeia and the General Test Method.
  • the dissolution rate at that time was obtained by comparison with the prepared standard solution.
  • Kollicoat ® ahyial compared with melo agarose each with povidone and Bottom Examples 1, 3 and 4 of the formulation is relatively high compared to the formulation of Comparative Example 2 with polyvinyl alcohol It can be seen that it shows the dissolution rate.
  • Finasteride is a drug that requires rapid dissolution to secure a high bioavailability, so Comparative Example 2 using polyvinyl alcohol is likely to cause a problem of lower bioavailability compared to Comparative Examples 1, 3 and 4.
  • Test Example 5 Dissolution test of a composite formulation containing a combination of a polyvinyl alcohol-polyethylene glycol graft copolymer and a polyvinyl alcohol as a coating base
  • Test Example 6 Defective test by core type of a composite formulation containing a combination of polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol as a coating base
  • Example 11 and Example 12 were also 1%. It was confirmed that a low failure rate appeared below. Therefore, the co-formulation of the present invention was confirmed that the second drug-containing film coating layer can be applied to various types of cores as well as hard capsule cores.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
PCT/KR2015/006743 2014-06-30 2015-06-30 활성성분-함유 필름 코팅층을 포함하는 복합제제 WO2016003181A1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES15816054T ES2772137T3 (es) 2014-06-30 2015-06-30 Preparación de composite que comprende una capa de recubrimiento pelicular que contiene principio activo
CN201580033728.7A CN106659690B (zh) 2014-06-30 2015-06-30 包括含有活性成分的膜包衣层的复合制剂
BR112016030731A BR112016030731A2 (pt) 2014-06-30 2015-06-30 Preparação de compósito, e, método de preparação de uma preparação de compósito
PL15816054T PL3162363T3 (pl) 2014-06-30 2015-06-30 Preparat złożony zawierający warstwę powłoki filmu zawierającą składnik aktywny
RU2016148824A RU2696563C9 (ru) 2014-06-30 2015-06-30 Композиционный препарат, включающий слой пленочного покрытия, содержащий активный ингредиент
EP15816054.9A EP3162363B1 (en) 2014-06-30 2015-06-30 Composite preparation comprising active ingredient-containing film coating layer
PH12016502537A PH12016502537A1 (en) 2014-06-30 2016-12-19 Composite preparation comprising active ingredient-containing film coating layer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2014-0081223 2014-06-30
KR20140081223 2014-06-30
KR10-2015-0093778 2015-06-30
KR1020150093778A KR101780739B1 (ko) 2014-06-30 2015-06-30 활성성분-함유 필름 코팅층을 포함하는 복합제제

Publications (1)

Publication Number Publication Date
WO2016003181A1 true WO2016003181A1 (ko) 2016-01-07

Family

ID=55019634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/006743 WO2016003181A1 (ko) 2014-06-30 2015-06-30 활성성분-함유 필름 코팅층을 포함하는 복합제제

Country Status (2)

Country Link
BR (1) BR112016030731A2 (pt)
WO (1) WO2016003181A1 (pt)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007252A (ko) * 2005-04-13 2008-01-17 바이엘 헬스케어 아게 양성 전립선 과다형성증용 치료 조합물
US20130171199A1 (en) * 2009-12-22 2013-07-04 Abbott Healthcare Private Limited Controlled release pharmaceutical composition
US20140010872A1 (en) * 2011-03-23 2014-01-09 Hanmi Pharm. Co., Ltd. Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007252A (ko) * 2005-04-13 2008-01-17 바이엘 헬스케어 아게 양성 전립선 과다형성증용 치료 조합물
US20130171199A1 (en) * 2009-12-22 2013-07-04 Abbott Healthcare Private Limited Controlled release pharmaceutical composition
US20140010872A1 (en) * 2011-03-23 2014-01-09 Hanmi Pharm. Co., Ltd. Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Technical Information, Kollicoat Protect, 03_040903e-08", BASF, PHARMA INGREDIENTS & SERVICES, February 2012 (2012-02-01), pages 1 - 10, XP055380857, Retrieved from the Internet <URL:http://www.pharma-ingredients.basf.com/Statements/Techcical%20Informations/EN/Pharma%20Solutions/03_040903e_Kollicoat%20Protect.pdf> *

Also Published As

Publication number Publication date
BR112016030731A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
KR101780739B1 (ko) 활성성분-함유 필름 코팅층을 포함하는 복합제제
WO2018070671A1 (ko) 레날리도마이드의 경구용 정제 조성물
EA002502B1 (ru) Фармацевтическая лекарственная форма, включающая 2-[[(2-пиридинил) метил] сульфинил] бензимидазол, обладающий противоязвенной активностью, и способ изготовления такой лекарственной формы
WO2019117502A1 (ko) 모사프리드와 라베프라졸을 함유하는 유핵정 복합제제
WO2013065936A1 (ko) 클로피도그렐 및 아스피린의 복합제제
ZA200602497B (en) Pharmaceutical compositions of moxifloxacin and processes for their preparation
WO2017160101A1 (ko) 클로피도그렐 및 아스피린을 포함하는 복합제제
WO2013162114A1 (ko) 위체류 약물전달 시스템을 이용한 서방성 제제
WO2018021772A1 (ko) 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
JP2008506679A (ja) 抗ヒスタミン組成物
US8563035B2 (en) Oral tablet compositions of dexlansoprazole
NZ281236A (en) Tablet (composition) comprising paracetamol (aceta-minophen) and domperidone (5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol -1-yl) propyl]-4-piperidinyl]-1,3-dihydra-2H-benzimidazol-2-one)
WO2021194253A1 (ko) 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법
WO2024186124A1 (en) Pharmaceutical formulation comprising esomeprazole or pharmaceutically acceptable salt thereof
WO2019199133A1 (ko) 레날리도마이드의 경구용 코팅 정제 조성물
WO2017146286A1 (ko) 친수성서방폴리머의 매트릭스를 이용한 은행잎 추출물의 약학조성물 및 이를 이용한 경구용 서방성 제제
WO2021118026A1 (ko) 프로톤펌프억제제 및 모사프리드를 포함하는 유핵정 제제
WO2012077968A2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2017150803A1 (ko) 에소메프라졸을 포함하는 제제
WO2020017808A1 (ko) 날푸라핀 함유 구강붕해정
WO2016003181A1 (ko) 활성성분-함유 필름 코팅층을 포함하는 복합제제
US20060204568A1 (en) Oral pharmaceutical preparation for proton pump antagonists
WO2021157883A1 (ko) 장용성의 프로톤펌프억제제 및 서방성의 모사프리드 제제를 포함하는 경질캡슐 제제
WO2016003180A1 (ko) 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
WO2016137266A2 (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15816054

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12016502537

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2015816054

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015816054

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016030731

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016148824

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016030731

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161228